Tumor Biology

, Volume 36, Issue 6, pp 4565–4573 | Cite as

Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer

  • Zhengjun Yang
  • Bin Zhang
  • Bowen Liu
  • Yegong Xie
  • Xuchen Cao
Research Article

Abstract

The purpose of this study was to investigate the prognostic value of Runx2 and Snail expression in breast cancer. The expression of Runx2 and Snail in clinical specimens from 125 breast cancer patients was detected by immunohistochemistry. The results showed there is a link between Runx2 and Snail expression at protein levels (p = 0.007). The Kaplan-Meier survival analysis showed that Runx2 or Snail expression was correlated with shortened disease-free survival (DFS) (p = 0.002, p = 0.004, respectively) and overall survival (OS) (p = 0.002, p = 0.009, respectively). In addition, Runx2-positive/Snail-positive patients had the worst DFS and OS (p = 0.001, p < 0.001, respectively). In multivariate survival analysis, Runx2, Snail, and combined Runx2/Snail were still remained as independent prognostic factors for DFS (p = 0.020, p = 0.013, and p = 0.001, respectively) and OS (p = 0.027, p = 0.030 and p = 0.005, respectively). These results suggest that a combined Runx2/Snail expression could be used as a new significant prognostic biomarker for patients with breast cancer.

Keywords

Breast cancer Prognosis Runx2 Snail EMT 

Notes

Acknowledgments

This research was funded by the National Natural Science Foundation of China (Grant no. 81372843) and the Tianjin Municipal Nature Science Foundation (Grant no. 11JCZDJC28000, 13JCYBJC21800).

Conflicts of interest

None

Supplementary material

13277_2015_3101_MOESM1_ESM.pdf (172 kb)
ESM 1 (PDF 172 kb)

References

  1. 1.
    Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2:61.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Orecchia R, Leonardi MC, Maisonneuve P, Morra A, Lazzari R, Cattani F, et al. Intraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience. Transl Cancer Res. 2014;3(1):59–64.Google Scholar
  3. 3.
    Zhang M, Li Z, Zhang X, Chang Y. Cancer stem cells as a potential therapeutic target in breast cancer. Stem Cell Investig. 2014;1:14.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(S1):S2–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Tan XF, Xia F. Long-term fatigue state in postoperative patients with breast cancer. Chin J Cancer Res. 2014;26(1):12–6.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Williams NR, Pigott KH, Brew-Graves C, Keshtgar MR. Intraoperative radiotherapy for breast cancer. Gland Surg. 2014;3(2):109–19.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Doisneau-Sixou S, Harbeck N. From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer. Chin Clin Oncol. 2014;3(2):16.PubMedGoogle Scholar
  8. 8.
    Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Wai PY, Mi Z, Gao C, Guo H, Marroquin C, Kuo PC. Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem. 2006;281:18973–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Endo T, Ohta K, Kobayashi T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab. 2008;93:2409–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci. 2010;101:2670–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.CrossRefPubMedGoogle Scholar
  14. 14.
    Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. Snai1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res. 2007;67:11721–31.CrossRefPubMedGoogle Scholar
  15. 15.
    van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, et al. Co-expression of snail and twist determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat. 2012;133:49–59.CrossRefPubMedGoogle Scholar
  16. 16.
    Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, et al. Transcription factor runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Investig J Tech Methods Pathol. 2012;92:1181–90.CrossRefGoogle Scholar
  17. 17.
    Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, et al. Regulation of breast cancer metastasis by runx2 and estrogen signaling: the role of SNAi2. Breast Cancer Res: BCR. 2011;13:R127.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by runx2/snail signaling pathway. J Biol Chem. 2011;286:37335–46.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007;211:532–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Li H, Zhou RJ, Zhang GQ, Xu JP. Clinical significance of runx2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:1807–12.CrossRefGoogle Scholar
  22. 22.
    Sase T, Suzuki T, Miura K, Shiiba K, Sato I, Nakamura Y, et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer. 2012;131:2284–93.CrossRefPubMedGoogle Scholar
  23. 23.
    Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, et al. Positive association between nuclear runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer. 2009;45:2239–48.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    McDonald L, Ferrari N, Terry A, Bell M, Mohammed ZM, Orange C, et al. Runx2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of runx2 perturbs differentiation in the mouse mammary gland. Dis Models Mech. 2014;7:525–34.CrossRefGoogle Scholar
  25. 25.
    Park SJ, Jung SH, Jogeswar G, Ryoo HM, Yook JI, Choi HS, et al. The transcription factor snail regulates osteogenic differentiation by repressing runx2 expression. Bone. 2010;46:1498–507.CrossRefPubMedGoogle Scholar
  26. 26.
    Osborne CK, Yochmowitz MG, Knight 3rd WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, et al. Runx3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, et al. Modulation of runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology. 2008;149:5984–95.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of n-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148:779–90.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zhengjun Yang
    • 1
    • 2
    • 3
    • 4
  • Bin Zhang
    • 1
    • 2
    • 3
    • 4
  • Bowen Liu
    • 1
    • 2
    • 3
    • 4
  • Yegong Xie
    • 1
    • 2
    • 3
    • 4
  • Xuchen Cao
    • 1
    • 2
    • 3
    • 4
  1. 1.Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerTianjinChina
  2. 2.Key Laboratory of Cancer Prevention and TherapyTianjinChina
  3. 3.Key Laboratory of Breast Cancer Prevention and TherapyTianjin Medical University, Ministry of EducationTianjinChina
  4. 4.The First Department of Breast CancerTianjin Medical University Cancer Institute and HospitalTianjinChina

Personalised recommendations